contiguous stage II marginal zone lymphoma
Showing 26 - 50 of >10,000
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent
Completed
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- +9 more
- Lenalidomide
- Rituximab
-
Houston, TexasM D Anderson Cancer Center
Sep 28, 2021
Marginal Zone B-cell Lymphoma Trial in Korea, Republic of (bendamustine plus rituximab)
Completed
- Marginal Zone B-cell Lymphoma
- bendamustine plus rituximab
-
Jeonju, Jeollabuk-do, Korea, Republic of
- +10 more
Sep 23, 2021
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)
Recruiting
- Acute Lymphoblastic Leukemia
- +12 more
-
Tucson, ArizonaThe University of Arizona Cancer Center
Dec 13, 2022
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Trial in Milano (intralesional rituximab, supplemental autologous
Completed
- Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
- intralesional rituximab
- supplemental autologous serum
-
Milano, ItalyDip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
Aug 2, 2022
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid
Completed
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- +99 more
- alemtuzumab
- +6 more
-
Denver, Colorado
- +6 more
Jan 15, 2020
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1
Active, not recruiting
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- +9 more
- Quality-of-Life Assessment
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Feb 3, 2022
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor
Recruiting
- Non-Hodgkin's Lymphoma
- +18 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Mar 11, 2021
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann
Completed
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- +11 more
- Laboratory Biomarker Analysis
- +2 more
-
Mountain View, California
- +90 more
Aug 3, 2022
Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,
Recruiting
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Scottsdale, Arizona
- +2 more
Jun 1, 2022
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +9 more
- Cryosurgery
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 9, 2022
Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Trial in Houston (Radiation Therapy)
Recruiting
- Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
- Radiation Therapy
-
Houston, TexasM D Anderson Cancer Center
Nov 9, 2021
Marginal Zone Lymphoma, Follicular Lymphoma Trial in Aurora (Ublituximab, Umbralisib)
Suspended
- Marginal Zone Lymphoma
- Follicular Lymphoma
-
Aurora, ColoradoUniversity of Colorado Hospital
Feb 22, 2022
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial
Active, not recruiting
- Contiguous Stage II Small Lymphocytic Lymphoma
- +11 more
- MOR00208
- +2 more
-
Columbus, OhioThe Ohio State University Comprehensive Cancer Center
Feb 24, 2022
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in
Completed
- Contiguous Stage II Mantle Cell Lymphoma
- +5 more
- bortezomib
- +9 more
-
Duarte, California
- +1 more
Jan 12, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +22 more
- Ibrutinib
- +3 more
-
Scottsdale, Arizona
- +1 more
Aug 10, 2021
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)
Recruiting
- Grade 3a Follicular Lymphoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Atlanta, Georgia
- +1 more
May 31, 2022
Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day
Recruiting
- Non Hodgkin Lymphoma (NHL)
- +6 more
- 8/12-Day Production of Car-T Cells
- +2 more
-
Milwaukee, WisconsinMedical College of Wisconsin and Froedtert Hospital
Jul 1, 2022
GVHD, Leukemia, Lymphoma Trial in Duarte (biological, drug, procedure, radiation, other)
Active, not recruiting
- Graft Versus Host Disease
- +2 more
- rituximab
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022
Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic
Completed
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- +115 more
- Fludarabine Phosphate
- +6 more
-
Denver, Colorado
- +10 more
Oct 29, 2019
Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult
Completed
- Contiguous Stage II Adult Lymphoblastic Lymphoma
- +5 more
- carfilzomib
- +10 more
-
Sacramento, CaliforniaUniversity of California Davis
Mar 8, 2022
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,
Terminated
- Non-Hodgkins Lymphoma
- +6 more
-
Huntsville, Alabama
- +1 more
May 5, 2022
Brain and CNS Tumors, Chronic Myeloproliferative Disorders, Leukemia Trial in Detroit (3'-deoxy-3'-[18F]fluorothymidine)
Recruiting
- Brain and Central Nervous System Tumors
- +8 more
- 3'-deoxy-3'-[18F]fluorothymidine
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Mar 30, 2022